Table 1

Baseline demographic and disease characteristics of patients receiving adalimumab+methotrexate in the DE019 study

Mean (SD)*DE019 (N=207)
Disease durationPrior DMARD treatment
≤1 year
n=9
>1–5 years
n=62
>5–10 years
n=43
>10 years
n=93
MTX+0–1
n=75
MTX+2
n=62
MTX+>2
n=70
Age, years55.2 (18.0)51.3 (15.7)56.6 (12.3)59.1 (11.1)58.7 (2.8)54.4 (14.7)54.7 (12.9)
Sex, female, n (%)5 (55.6)48 (77.4)33 (76.7)72 (77.4)58 (77.3)50 (80.7)50 (71.4)
RA duration, years0.7 (0.2)3.1 (1.3)7.1 (1.3)19.1 (8.0)9.3 (10.4)11.3 (9.3)12.6 (7.5)
Prior DMARD treatments†1.4 (0.5)2.0 (1.2)2.1 (1.3)2.7 (1.6)1.0 (0)2.0 (0)4.0 (1.1)
DAS28(CRP)6.4 (1.1) n=85.6 (0.8) n=465.7 (0.9) n=295.8 (0.7) n=695.7 (0.9) n=545.8 (0.8) n=475.7 (0.8) n=51
SDAI49.0 (17.2) n=838.5 (11. 8) n=4640.1 (13.1) n=2941.6 (11.1) n=6940.0 (12.1) n=5441.9 (12.0) n=4740.6 (12.5) n=51
HAQ-DI1.6 (0.9) n=81.3 (0.7) n=461.3 (0.6) n=291.5 (0.6) n=691.4 (0.7) n=541.4 (0.6) n=471.4 (0.7) n=51
  • *Values are means (SD) unless specified otherwise.

  • †Including methotrexate.

  • DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; RA, Rheumatoid arthritis; SDAI, Simplified Disease Activity Index.